+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07559331

Study Comparing High-Dose Dexamethasone With Orelabrutinib or Placebo in Adults With Newly Diagnosed Primary Immune Thrombocytopenia

Led by Shandong University · Updated on 2026-04-30

86

Participants Needed

1

Research Sites

90 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a treatment for adults newly diagnosed with Primary Immune Thrombocytopenia ITP, a condition affecting platelet counts. This Phase 3 randomized controlled trial compares high-dose Dexamethasone combined with Orelabrutinib against high-dose Dexamethasone combined with a placebo to understand their effects on this condition. The study is led by Shandong University and aims to measure the overall response rate over an average of 6 months. Participants will receive either Orelabrutinib 50 mg once daily for 3 months combined with Dexamethasone 40 mgday for 4 days, or a matching placebo once daily for 3 months combined with the same Dexamethasone regimen. The trial includes two groups one receiving the active combination and one receiving placebo with Dexamethasone. Treatment is given under close monitoring in a double-blind, randomized approach. During the study, participants will be monitored for their platelet response and bleeding status, with regular blood tests to track platelet counts and other safety measures. The main outcome is the overall response rate throughout approximately 6 months, with additional assessments at 1, 2, and 3 months. Participants will be followed closely for safety and treatment response throughout this period.

CONDITIONS

Brief Title

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Research Team

M

Min Hou, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here